Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC36A3 (Solute carrier family 36 member 3, also known as PAT3 or TRAMD2) is a predicted proton-coupled amino acid transporter belonging to the SLC36 family and the larger AAAP family within the APC superfamily[3][5]. It is primarily expressed in the testes and remains classified as an orphan transporter with no currently established physiological function or confirmed substrate specificity[2][3]. Unlike its well-characterized paralogs SLC36A1 and SLC36A2, which mediate the H^+-symport of amino acids in the intestine and kidney, SLC36A3's biological and pathological roles are unknown. Early functional annotations suggest transmembrane transport of amino acids and carboxylic acids, but this has not yet been confirmed in vivo[5]. Current research on SLC36A3 is limited, with no known direct association with disease, no validated drug interactions, and no clinical or pharmacological exploitability at this time[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 36 member 3 (SLC36A3).